HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics (NASDAQ: IOVA) and maintained a price target of $32.
June 28, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics and maintained a price target of $32.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100